Last reviewed · How we verify
Integrase Inhibitor
Integrase inhibitors block HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.
Integrase inhibitors block HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA. Used for HIV-1 infection (as part of combination antiretroviral therapy).
At a glance
| Generic name | Integrase Inhibitor |
|---|---|
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Drug class | Integrase inhibitor |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
HIV integrase is an enzyme that catalyzes the integration of viral DNA into the human genome, a critical step in HIV replication. By inhibiting this enzyme, integrase inhibitors prevent viral DNA from becoming incorporated into host chromosomes, thereby blocking productive infection and viral replication. This class is used as part of combination antiretroviral therapy for HIV-1 infection.
Approved indications
- HIV-1 infection (as part of combination antiretroviral therapy)
Common side effects
- Nausea
- Diarrhea
- Headache
- Insomnia
- Elevated creatinine kinase
Key clinical trials
- A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV (PHASE1)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana (PHASE4)
- DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old (PHASE2, PHASE3)
- Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) (PHASE3)
- Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV (EARLY_PHASE1)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: